Key Points
- Insider sale: Mark Goldsmith sold 20,000 shares on Nov. 18 at an average price of $70.38 for proceeds of $1,407,600, reducing his stake by 7.47% to 247,863 shares (SEC filing disclosed).
- Earnings miss and outlook: Revolution Medicines reported EPS of ($1.61) vs. a ($1.39) estimate (missing consensus), analysts forecast a -3.49 FY EPS and the consensus price target is about $78.50 with most analysts rating the stock a Buy/Strong Buy.
- Market/valuation snapshot: NASDAQ:RVMD has a market cap of $13.51B, a negative P/E (-13.52), a 12‑month range of $29.17–$72.72 and recent price momentum (50-day MA $53.42 vs. 200-day MA $43.71).
Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) insider Mark Goldsmith sold 20,000 shares of the firm's stock in a transaction dated Tuesday, November 18th. The shares were sold at an average price of $70.38, for a total value of $1,407,600.00. Following the transaction, the insider owned 247,863 shares of the company's stock, valued at approximately $17,444,597.94. The trade was a 7.47% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.
Revolution Medicines Price Performance
NASDAQ:RVMD opened at $69.88 on Friday. The company has a current ratio of 8.05, a quick ratio of 8.05 and a debt-to-equity ratio of 0.16. The company has a market capitalization of $13.51 billion, a P/E ratio of -13.52 and a beta of 1.25. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $72.72. The business's 50-day moving average is $53.42 and its 200 day moving average is $43.71.
Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($1.61) earnings per share for the quarter, missing the consensus estimate of ($1.39) by ($0.22). During the same quarter last year, the firm posted ($0.94) earnings per share. On average, equities research analysts forecast that Revolution Medicines, Inc. will post -3.49 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Revolution Medicines
Institutional investors have recently made changes to their positions in the company. CWM LLC boosted its stake in shares of Revolution Medicines by 171.3% during the 2nd quarter. CWM LLC now owns 917 shares of the company's stock worth $34,000 after purchasing an additional 579 shares during the period. GAMMA Investing LLC boosted its position in shares of Revolution Medicines by 45.1% during the third quarter. GAMMA Investing LLC now owns 837 shares of the company's stock valued at $39,000 after buying an additional 260 shares during the period. Banque Transatlantique SA bought a new position in shares of Revolution Medicines during the first quarter valued at approximately $42,000. Quarry LP bought a new position in shares of Revolution Medicines during the first quarter valued at approximately $50,000. Finally, Twin Tree Management LP purchased a new stake in shares of Revolution Medicines in the first quarter worth approximately $58,000. Institutional investors own 94.34% of the company's stock.
Analysts Set New Price Targets
Several equities research analysts recently weighed in on RVMD shares. National Bankshares set a $80.00 price target on shares of Revolution Medicines in a research report on Friday, October 17th. Raymond James Financial lifted their price objective on shares of Revolution Medicines from $72.00 to $76.00 and gave the stock a "strong-buy" rating in a research note on Friday, October 17th. Mizuho initiated coverage on shares of Revolution Medicines in a research report on Tuesday, October 21st. They set an "outperform" rating and a $90.00 target price on the stock. JPMorgan Chase & Co. increased their price target on shares of Revolution Medicines from $71.00 to $82.00 and gave the company an "overweight" rating in a report on Thursday, November 6th. Finally, Lifesci Capital began coverage on Revolution Medicines in a research note on Monday, August 18th. They set an "outperform" rating and a $80.00 price objective on the stock. Three research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines has an average rating of "Buy" and a consensus target price of $78.50.
View Our Latest Research Report on RVMD
Revolution Medicines Company Profile
(
Get Free Report)
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
